Canopy Growth Corp Q2 FY2025 Earnings Call

Good morning. My name is Nicole, and I will be your conference operator today. I would like to welcome you to Canopy Group's Second Quarter Fiscal 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode. I will now turn the call over to Tyler Burns, Director of Investor Relations. Tyler, you may begin the conference call.

Good morning and thank you for joining us. On our call today, we have Canopy Growth's Chief Executive Officer, David Klein, and Chief Financial Officer, Judy Hong. Before markets open today, Canopy Growth issued a news release announcing the financial results for our second quarter fiscal year 2025 ended September 30, 2024. This news release and financial statements have been filed on EDGAR and SEDAR and will be available on our website under the Investors tab. Before we begin, I would like to remind you that our discussion during this call will include forward-looking statements that are based on management's current views and assumptions and that this discussion is qualified in its entirety by the cautionary note regarding forward-looking statements included at the end of the news release today. Please review today's earnings release and Canopy's reports filed with the SEC and SEDAR for various factors that could cause actual results to differ materially from projections. In addition, reconciliations between any non-GAAP measures to their closest reported GAAP measures are included in our earnings release. Please note that all financial information is provided in Canadian dollars unless otherwise stated. Following remarks by David and Judy, we will conduct a question-and-answer session, where we will take questions from analysts. With that, I turn the call over to David.

Thanks, Tyler. Good morning and thank you for joining us to discuss Canopy Growth's results for the second quarter of fiscal 2025. We've had a busy and productive quarter led by outstanding performance from stores as well as solid progress across our Canadian and medical and European medical cannabis businesses. In addition, we've taken substantial steps forward in our Canadian adult-use cannabis business, which we feel is well set up for growth in the second half of the year. Overall, Canopy's performance in each of these areas supports our strategy to drive sustainable profitability as well as to build a competitive foundation for long-term success across North America and key global markets, especially when we combine the growing momentum within Canopy USA, which we feel continues to set us apart from our competition as this strategy was specifically designed to succeed independent of the need for U.S. federal legalization. During the call today, I'll cover three main topics: first, the exceptional performance of Storz & Bickel device business as well as our medical cannabis businesses. Second, I'll address our continued focus on profitability in Canada and the actions we're implementing to drive growth in our Canadian adult-use cannabis business in the second half of fiscal 2025. And third, I'll update you on the developments happening within Canopy USA, which we believe is well positioned to capture significant growth in the U.S. cannabis and hemp-derived markets. Following my remarks, Judy will provide a detailed overview of our results, market conditions and the actions we've taken to further strengthen our financial standing. So let's start with Storz & Bickel in our medical cannabis business, which performed very well in Q2. These segments are critical drivers for Canopy, particularly as they are high-margin and align with our focus on expanding within our existing markets, which are demonstrating strong and consistent demand. Our German-based Storz & Bickel business known for premium devices like the Volcano and Venti, delivered overall net revenue growth of 32% year-over-year. This exceptional performance was in part driven by the brand's well-established reputation among German consumers, extensive in-market activities as well as increased demand following the reform of cannabis regulations this past April. Beyond Germany, Storz & Bickel also saw the resumption of strong growth in the U.S., led by increased orders from new distribution partners. The growth across these markets was driven by strong sales of the recently launched Venti as well as sell-through of inventory of the Mighty classic vaporizer, which is being phased out in favor of the Mighty+. Overall, the achievements of Storz & Bickel in the quarter underscore how the brand's premium position in the market and portfolio innovation are driving our growth in high-margin device sales. Our medical cannabis businesses in Canada and Europe also produced great results in Q2. Our Canada Medical business delivered an outstanding second quarter with revenues up 16% year-over-year. This growth is a result of the continued expansion of the product selection in our Spectrum online store as well as constant availability, which are enabling us to capture a progressively larger share of the high-margin Canadian medical cannabis market, particularly as we see more insured patients accessing Spectrum for their medical cannabis needs. On the international front, demand continues to be robust, driving substantial year-over-year revenue growth. This reinforces the potential that we see across the high-margin European markets where Canopy's revenues are up 72% year-over-year. In Germany, our medical cannabis revenue surged by 47% from the first to the second quarter demonstrating the rapidly rising demand in Germany's medical market since legalization and Canopy's positioning as one of the long-term players within that market. In Poland, our revenues grew 200% year-over-year. It's also worth noting that this European growth is currently being largely supported by our Kincardine GMP cultivation. However, our asset-light model for Europe is now coming online, supported by agreements with multiple EU-based cultivators and we expect this will provide the scalability that we need to meet rising demand over the coming quarters without the need for heavy capital investments. This approach not only preserves our flexibility, but also supports strong gross margins across our international medical business. Now, let's dive a bit deeper into our Canadian adult-use business. With our improved cost structure, we're highly focused on profitably growing the top line in Canada. To power this growth, we're executing several targeted initiatives to drive back to its position of leadership in the edibles category, rejuvenate and strengthen the competitive position of our core flower offerings and to bring new and innovative products to market. I'm pleased to share that the production of Wana edibles is fully resumed within the quarter and supply is now coming back into retailers across Canada as well as into the Spectrum online store, supported by in-market activations and by tender education. In addition, we anticipate bringing new premium and better-for-you Wana gummies to the Canadian market early in the New Year as part of our focus on delivering innovation to consumers. In our core portfolio, the quality and variety of Tweed and 7ACRES product offerings within the flower as well as pre-roll joint segments is driving consumer demand. And by further honing our production platform and its ability to cultivate high-quality strains with elevated and consistent THC levels, we've strengthened the competitive positioning of these brands in the market. We're seeing this pay off through the reinvigorated performance of Tweed Cushmans and a significant uptake of Tweed Cherry Acai Mints, which is now carried in all markets nationally. In addition, as a sign of things to come, our team was thrilled to bring 7ACRES Ultrajack to markets. Ultrajack, for those who haven't yet had a chance to sample it, is a homegrown 7ACRES creation. The brand will also be bringing back a number of historically high-performing strains to consumers over the coming months. In parallel, we're investing in efforts to increase the distribution of our flower and PRJ offerings and have been very encouraged to see the distribution of our Tweed flower products increased by over 10% this quarter. Finally, to improve the performance of our adult-use business, we're investing in a robust NPD pipeline with a particular focus on the growth categories of pre-rolled joints, vapes, and concentrates. One such example coming to market is an innovative brand of infused pre-rolled joints that's a top seller in California and will be available to consumers in the next month. Early feedback from provincial cannabis stores and retail partners has been overwhelmingly positive. We're confident that this new product lineup in the high-margin pre-roll category will resonate well with consumers and contribute meaningful revenue over the coming quarters. In addition to new flower offerings, new game-changing infused pre-rolls, and health-conscious innovation from Wana, we'll also be bringing to market a number of limited-time-only beverage and flower SKUs just in time for the holiday season. Overall, our focus remains on investing to continually enhance our product quality, increase distribution, and bring new and innovative products to delight our consumers. Finally, looking to the U.S., I'd like to provide an update on the accelerating momentum occurring within the Canopy USA ecosystem. In the second quarter, Canopy USA closed the acquisition, and I'm pleased to report that the acquisition remains on track for completion no later than the first half of calendar year 2025. Canopy USA's Wana brand also launched Wonderous, a new marketplace for hemp-derived THC and CBD products as the brand expands its reach to access a new national customer base. Canopy USA's Jetty brand is gearing up to introduce a new line of solventless all-in-one vapes in California and Colorado with a planned launch in New York early next year. Finally, at Acreage, work remains underway to leverage the improved capital structure to strengthen the fundamentals of the business, streamline costs and drive growth in priority states where Acreage holds a strong foothold, including Ohio. The ecosystem approach, which will integrate the best of Wana, Jetty, and Acreage will enable Canopy USA to leverage synergies across these brands, optimize existing market positioning, and capitalize on immediate growth opportunities as a differentiated and brand-driven platform. Overall, we're confident that Canopy USA is well positioned to deliver significant value for our shareholders over time, including as new U.S. markets come online for adult use. Finally, while we would have liked to see a positive outcome in Florida, our view remains that Canopy USA is ideally set up to thrive in the current environment, independent of federal legalization. And while we would welcome future movement on Safe Banking or 280E reform by rescheduling, the strength of our approach is that we are not dependent on this taking place in the immediate term. Overall, we're proud of the progress made this quarter as we continue to strengthen and grow our core businesses, advance our profitability at the enterprise level, and position Canopy USA for long-term growth. I'll now turn the call over to Judy.

Thank you very much, David, and good morning, everyone. I'll start by reviewing our second quarter fiscal 2025 results, including performance by key business units. I'll then discuss continued progress we've made on our balance sheet and cash flow, followed by a discussion on our priorities and outlook for the balance of fiscal 2025. Let's begin with our second quarter results. Q2 FY2025 was a solid quarter overall with strong revenue growth in Storz & Bickel and our medical cannabis businesses driving year-over-year improvement in gross margins, adjusted EBITDA, and free cash flow. Canopy delivered consolidated net revenue of $63 million in Q2, a decrease of 9%, or an increase of 3% excluding the impact of divested businesses compared to Q2 of last year. Consolidated gross margin in Q2 was 35%, a 100 basis point improvement compared to last year. I'm pleased to see consistent gross margin performance in our overall business as we've now delivered gross margins in the mid-30% for four out of the past five quarters. Q2 adjusted EBITDA was a loss of $6 million, an improvement of 54% versus last year. And free cash flow was an outflow of $56 million, an improvement of 16% compared to Q2 of last year. As I noted during our Q1 earnings call, we typically incurred negative working capital in the first half of the fiscal year due to the timing of certain payments, but we expect significant improvement in the second half. I'd like to now review the results of our key businesses in more detail, starting with Canada. Q2 net revenue was $37 million, a decline of 8% compared to a year ago. Canada Medical continued its momentum with revenue growth of 16% compared to last year as our medical customer mix continues to shift towards a greater number of insured patients and we're expanding our product assortment to meet the needs of our customers. The overall Canada medical market is also now seeing modest growth and we're pleased with the continued outperformance in our Canada Medical sales, which is also a high-margin business for us. The growth in Medical was offset by our Canada adult-use business, which was down 24% year-over-year. Our Canada adult-use business did not show the expected sales improvement in Q2, in part due to a supply interruption of Wana edibles, resulting from financial challenges faced by its contract manufacturer. We estimate that not having a sufficient Wana supply during Q2 drove approximately $3 million of negative revenue impact for our total Canadian business. We've since addressed the supply interruptions and expect to see improved Wana performance in the second half. Canada gross margin in Q2 was 32%, and cash gross margin, adding back non-cash depreciation cost, was 43%. This is the second consecutive quarter of cash gross margin in the mid-40% in Canada as the growth in our medical business, which carries higher margins than our adult-use business, is contributing to strong gross margin performance. During Q2, our medical business accounted for more than half of revenue in Canada. As we focus on accelerating growth in our adult-use business, we expect Canada's cash gross margins to revert back to our target of mid to high 30%. International markets' cannabis net revenue of $10 million in Q2 FY2025 was up 12% compared to Q2 of last year. We saw strong growth in Poland and Germany, which was partially offset by the decline in sales in our Australian medical cannabis business, driven by increased price competition. International markets' cannabis gross margin was 47% in Q2 FY2025, up from 30% in Q2 of last year, driven by a favorable shift in country mix, with higher margin pulling in contributing to a greater portion of sales this quarter as compared to the prior year period and overall loss to lower cost structure. Storz & Bickel had an exceptional quarter with revenue of $16 million in Q2 and was up 32% compared to last year. Key drivers include strong growth in Germany following regulatory reform, significant improvement in U.S. sales compared to the year-ago period, as well as the final sell-through of the Mighty vaporizer, which is going through a planned phase-out. We also note that last year's Q2 did not include any sales from Venti as the product was launched during Q3 of last year. We did see a significant decline in shipments to Australia in Q2 following a recent regulatory change. However, we continue to see Storz & Bickel medical vaporizers as well positioned in the medical channel in Australia, given their unique status as the only medical approved old flower vaporizers. Storz & Bickel gross margin was 32% compared to 33% last year. Q2 gross margin is typically lower for Storz & Bickel and margin was also impacted by higher rebates on Mighty. Looking at our SG&A expenses for Q2 of fiscal '25, sales and marketing and G&A expenses have combined declined 20% year-over-year, primarily due to the cost reduction program undertaken during fiscal 2024. Year-to-date, our corporate G&A costs have also declined by nearly $10 million versus the prior year and we're well on track to achieve $10 million to $15 million additional cost reductions by the end of this fiscal year. Q2 fiscal 2025 adjusted EBITDA was a loss of $6 million compared to a loss of $12 million a year ago. We estimate that our three business units again achieved positive adjusted EBITDA in Q2 with all of the Q2 adjusted EBITDA losses driven by unallocated corporate overhead costs, including public company costs. I'd like to now review our cash flow and balance sheet. Free cash flow was an outflow of $56 million in Q2, an improvement of 16% compared to the prior year. Cash used from continuing operations was $54 million. This included cash interest payments in the quarter of $18 million, down from $28 million in Q2 of last year. Similar to Q1, we incurred negative working capital in Q2, driven by certain timing of payments as well as higher inventory builds in Canada, but we expect free cash flow to narrow significantly in the second half of the year versus the first half run rate to reflect the timing of payments and continued reduction in interest expenses. Turning to the balance sheet. As of September 30, 2024, we had $231 million in cash and short-term investments and a total principal debt balance of $574 million. In October, we further reduced our term loan balance by USD100 million by making an early prepayment, bringing the total term loan principal balance to approximately USD250 million. This will also reduce our annualized interest expenses by approximately USD14 million. We have an option to further extend the maturity of the term loan to September 2027 from December 2026, if we choose to make an additional USD100 million payment at USD97.5 to par before the end of March 31, 2025. Under the current ATM program that was launched in June, to date, we've generated total gross proceeds of USD149 million. We believe we have ample cash on our balance sheet to meet our near-term obligations and the remaining ATM program should provide us with the flexibility to invest in growth initiatives. I'd like to now briefly discuss Canopy USA. As David mentioned, Canopy USA has completed its acquisition of Wana and Jetty and is on track to close an Acreage acquisition no later than in the first half of calendar 2025. Let me provide some commentary on the performance of each entity. Acreage management continues to focus on improving performance in its core states with its year-to-date results impacted by its credit challenges earlier in the year. The launch of non-medical sales in Ohio was delayed and full adult-use sales have not begun. Further, as indicated by other market participants, growth in Ohio has yet to benefit significantly from the opening of the non-medical markets given restrictions around marketing and product formats. That said, with five stores currently operating in Ohio and the ability to open an additional three stores, Acreage management believes it's well positioned to show significant growth once the market fully opens for adult use. Turning to Wana. Year-to-date, Wana's performance has been somewhat hindered by slower-than-expected launches in New York and Ohio, as well as lower licensing revenue in Canada due to the supply interruption. Wana is focused on expanding into new states and has solidified the launch of its East Coast markets, which now includes New York, New Jersey, Massachusetts, Vermont, Connecticut, and Maryland. Wana also launched a hemp-derived marketplace in August, with sales seeing gradual improvement. Jetty is seeing strong underlying momentum and has successfully transitioned its distributor in California with minimal disruption. With the new distribution partner now in place to drive enhanced market expansion at reduced cost, Jetty is focused on expanding its lineup of solventless vape offerings into California, Colorado, and New York. I'd like to now provide our key priorities and outlook for the balance of fiscal '25. In Canada cannabis, we expect continued strength in our medical business and improved performance in our adult-use business in the second half of fiscal 2025, driven by Wana supply being restored, additional investments driving expanded distribution and improved velocity for our core products as well as new product launches. In international markets cannabis, we're focused on ensuring consistent supply of high-quality products as well as launching new products to meet demand in Poland and Germany, while actions are underway to strengthen our competitive positioning in Australia. For Storz & Bickel, we expect growth to continue in the second half, with Q3 benefiting from higher contribution from Venti compared to last year, while Q4 growth is likely to be more muted due to exceptionally strong sales of the device following its launch quarter in fiscal '24. Finally, the impact from divested businesses will continue to negatively impact reported sales growth throughout fiscal 2025. Q3 FY'24 revenue included approximately $9 million of revenue from divested businesses. So with expected improvement in top line growth in the second half and continued cost discipline, we believe we remain on a path to achieve positive adjusted EBITDA at the consolidated level in the coming quarters, with our focus on driving long-term sustainable growth in our businesses while continuing to find additional opportunities for cost efficiencies. This concludes my prepared comments. We'll now take questions.

So question I want to ask is regarding the hemp initiative that you have here in the U.S. Just looking at the Wonderous website by Wana, you guys have both edibles and beverages. So do you want to give some greater color in terms of planned distribution initiatives? Are you able to leverage any relationships with Constellation on the beverage side? I know that's been a big push for a lot of companies out there with the growth in hemp beverages. So any color you could offer on that? And then how you're seeing potential for regulatory reform through THC cannabinoids via hemp versus cannabis and how that could impact your decision there?

I believe that the opportunity for hemp-derived offerings in the U.S. is massive. And I'll start with the last part of your question first. I think our view is, for the most part, it will be left up to the states to determine the path forward. And we're prepared to work in that environment. Our first step in this, and when I'm saying our, I mean, Wana's step in this activity was to get themselves set up from a direct-to-consumer standpoint. As part of the QC infrastructure, they brought over the Martha Stewart CBD offerings as well as putting their own offerings in and, quite frankly, working with partners to go direct to consumer. So that was step one. There is a lot of engagement going on right now from a B2B standpoint to get on the shelf at retail. And that pathway is heavily influenced or being addressed anyway by beverage alcohol distributors. And of course, the connections that Canopy has in that industry are very valuable in trying to establish that B2B marketplace for ourselves. So, we're really excited about hemp. We're really early in that process. The entire industry is, but we think it could be huge.

Just on the comment on Australia, the competitive dynamics in that market. I'm just curious, how do you plan to, I guess, become more competitive there on the pricing side? I mean what initiatives are you going to be implementing to achieve that?

So in Australia, we've actually had pretty good growth over the last few years as we've been able to really supply that market out of Canada. I think as you've seen other players really leverage some of the Canadian supply to service the Australian market, you've seen increased competition, the number of players have gone up and then you've started to see more price competition taking place similar to, frankly, what you've seen in the Canadian market. We are really looking to take advantage of our supply opportunities in Canada with our lower cost structure, obviously working with partners and making sure we've got an ample supply in place to service that market with the better cost structure. And we are also focused on just making sure we're going to the market with a broader assortment of products in the marketplace.

I noticed that the outlook for adjusted EBITDA turning positive has shifted. You mentioned a timeline of the coming quarters instead of the second half as before. Is this a change, and if so, what is causing the potential delay?

So look, I mean, we're very pleased with the continued progress that we're making on our consolidated adjusted EBITDA. I think we're seeing good performance out of all of our businesses. And as I said on the call, all of our business units have delivered positive adjusted EBITDA. We are also making progress on reducing our corporate G&A costs, and we've already reduced, on a year-to-date basis, $10 million and we think we'll see additional cost opportunities in the back half of the year. Our expectation around second-half positive adjusted EBITDA was partly predicated on more growth coming from our Canada adult-use businesses. We're confident that we will see improved growth in the back half. It's just the timeline of getting the growth in the second half from a pace and timing perspective is really what we're thinking about as we think about when we can achieve that positive adjusted EBITDA. The other thing I would just want to point out is that we are really building a business that is able to achieve positive adjusted EBITDA kind of quarter in and quarter out. So we also want to make sure that all of our businesses are getting to the physician where consistently they're delivering an adjusted EBITDA positive basis, and we're confident that we're nearing that point.

Just wanted to touch on international. You called out a pretty big growth rates in Europe and specifically mentioned Germany and Poland. But overall, obviously, it was still more subdued. And so maybe just how intense was the price competition in Australia? How big of a headwind was that? And is there any way to get a sense in so many cases, we've seen some version of it's just pretty much a matter of time before price competition creates some of these headwinds in markets over the last few years. Is there structural differences in Poland and Germany that help mitigate or mute that? And what should we expect looking ahead a little bit?

I would like to make a few points. Firstly, we have intentionally concentrated our supply on high-margin markets such as Germany, Poland, and our Canadian Medical business, while also focusing on Storz & Bickel. In markets that have been more challenging, like Australia and the Canadian adult-use sector, we are actively working to enhance our positioning, but are prioritizing the high-margin aspects of our business. Regarding Australia, we have taken steps this quarter, including expanding our product offerings and adjusting pack sizes, which will help us be more competitive. However, as you noted, every market eventually faces price compression. What gives me confidence at Canopy is that Canada may be one of the toughest markets to compete in globally. We have established a cost-effective infrastructure for growth and back office operations, which has resulted in attractive gross margins. Therefore, we believe we are well-prepared to compete in these markets as prices compress. Now, concerning Germany and Poland, Poland operates differently since sales must go through the government, which provides some near-term protection. I believe that Germany will eventually follow the trend seen in other developed markets. While it may take some time, we anticipate capacity will increase in Germany, leading to lower costs. We are spending considerable time strategizing for this eventuality, ensuring we can lead aggressively in that market rather than being caught off guard. Our infrastructure in Germany has been designed to be asset-light because we have seen the advantages of this approach elsewhere. Indeed, every market goes through periods of favorable pricing followed by compression before normalizing. We believe that normalization in Germany is still some time away, but we are ready to endure and succeed when that time comes.

I just wanted to get a bit more clarification potentially, Judy, on some of your comments on the cash flows and the balance sheet. So we look at kind of the first six months of the fiscal year and we're a little over $100 million in free cash flow burn. And I know a lot of that is working capital fluctuations or at least I assume that a chunk of it is. When you say it will narrow significantly, I'm just trying to get an idea of maybe on a relative basis, the quantum. And then further, just the ATM that's being used in the interim, just given some of the price action we saw on the back of the U.S. election, if there's any changes to the cadence we're seeing of that being utilized?

Yes. So on the cash flow side, so as you point out and as I mentioned on the call, the first run rate is typically much higher, and a lot of that is because of the timing of payments that includes insurance premiums. We also have prior year bonus payments, the timing, and then the Health Canada fees. So all of those have hit the first half of the year, and those are amounts that won't be repeated in the second half. So our expectation is in the second half, when you look at the cash outflow, I do estimate that to be close to half of what we saw in the first half of the year. The interest payments also would be lower as we paid down the $100 million of additional term loan; we would see a reduction in the interest payment. We would expect to very tightly manage the working capital and just the timing of the payments now working more in favor in the back half versus the first half. And finally, the CapEx is also likely to be more modest in the second half versus the first half, just given some of the timing of the investment. So that would be my expectation for the back half of the cash flow.

David, my question is one around Canopy USA. Can you talk about room there for expansion in the way of acquiring more brands beyond Wana and Jetty? And also, maybe remind us of how you're going to accelerate the expansion or the room for growth for both Wana and Jetty in the case of Wana going to go deeper in the state? Is there room to license in other states? Can you even go vertically in some cases, given and follow more of the Jetty model? And in the case of Jetty, you said New York, Colorado, California, is there room to add more states? So that's the first part of your question regarding kind of USA growth opportunities. And then the second part is that back in the day, you used to mention the term federal permissibility. We are waiting for the Acreage deal to close June next year. But in practical terms, pretty much you can do almost most of the things you want to do around Canopy USA at the moment, right? And correct me if I'm wrong, even though we don't have permissibility, and the deal on Acreage hasn't closed, or at least just explain what else could you do once those things happen compared to what you're going to do now around Canopy USA?

Honestly, I'm not sure what federal permissibility really means anymore. It appears that the path forward will likely involve a series of regulatory reforms that resemble federal legalization. To address your question, our structure allows our investors to engage with the U.S. THC market while still trading on the U.S. exchange, which was designed for this lengthy journey toward federal permissibility. We remain hopeful and interested in initiatives like 280E reform and safe banking, which the President-elect has agreed to support. These would benefit our U.S. operations financially, but they're not essential for our structure to function. This unique structure enables us to expand Canopy USA effectively. The team at Canopy USA is dedicated to executing at Acreage, focusing on a strategy that emphasizes strengthening our presence in our current markets rather than expanding too broadly. We aim to optimize our production resources at Acreage to enhance our other brands like Wana and Jetty. For Jetty, expansion will center on developing its core innovation, particularly solventless capabilities, which we believe significantly sets the Jetty brands apart. We're looking to establish that strength in every market because it differentiates us. Additionally, there are prospects for Jetty to be manufactured in Acreage's markets. Jetty and Wana are already working together to leverage their combined strengths in calling on retail accounts. Regarding Wana, its expansion is also about deepening our presence; we want to increase shelf space in the states we're in while putting effort behind the broader portfolio we discussed earlier. Our differentiated brand-led strategy across the U.S. market is compelling. We will continue to seek partnership opportunities with other industry players, particularly given the potentially lengthy timeline for federal legalization, which we believe will create excellent growth opportunities for CUSA.

There are no questions in the queue. I will now turn the call over to Mr. Klein for final remarks.

Great. Thanks for attending today's conference call. For those in Canada, as you enjoy the fall and prepare for the holidays, be on the lookout for the PRJ innovation that we talked about, which should be arriving in stores over the next few weeks. And for those of you in the U.S., yes, please visit shopwonderous.com to take a look at the great hemp-derived product offering that's currently available for shipment to your home. Our Investor Relations team will be available to answer additional questions throughout the day. Thanks, everyone.

This concludes Canopy Group's second quarter fiscal 2025 financial results conference call. A replay of this conference call will be available until February 6, 2025 and can be accessed following the instructions provided in the company's press release issued earlier today. Thank you for attending today for today's call. Have a good day, everyone.